Menarini

Insilico Medicine, Menarini sign second $500M+ cancer drug deal

Their second exclusive, global in-licensing covers a second small molecule inhibitor, this time targeting what they described as a variety of solid tumors.

Conor Hale Jan 10, 2025 9:30am

Insilico nabs $500M+ biobucks deal for preclinical cancer asset

Jan 4, 2024 10:00am

Context cuts excess fat to carry biotech into ‘24

Sep 28, 2022 11:00am

As Sanofi's SERD falls, Menarini's advances with EU review

Aug 19, 2022 9:20am

Menarini, chased by 3 Big Pharmas, records breast cancer win

Oct 21, 2021 7:05am

Debiopharm buys ImmunoGen ADC to grow cancer pipeline

May 24, 2017 4:26am